A Phase IIa Trial of the Oral JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM
Status:
Not yet recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
This study aims to investigate the clinical efficacy of baricitinib in patients with adult
idiopathic inflammatory myositis (IIM). Half of the patients enrolled onto the study will
receive 24 weeks of baricitinib from the baseline visit with a 12 week follow-up period. The
other half of patients will receive barcitinib treatment after an initial 12-week delay with
a 4 week follow up period for safety.
Phase:
Phase 2
Details
Lead Sponsor:
University of Manchester
Collaborators:
Eli Lilly and Company Karolinska Institutet Manchester Clinical Trials Unit